Our commitment to patients drives everything we do. The AURORA Phase 3 trial is evaluating a potential new treatment option for myasthenia gravis (#MG), designed for convenient outpatient dosing and no pretreatment chemo. See if you may qualify: https://t.co/NT0uoYZMSV

We had a great time at our annual #Thanksgiving party! Thanks to our partnership with Beyond Shelter Frederick, we were able to give back to our community by hosting a supply drive to help in their mission of preventing and alleviating the effects of poverty in Frederick County.

Following our launch of "The Might and Grace Networkᵀᴹ - A MG Patient Ambassador Program", we hosted a patient ad-board with ambassadors living with gMG or caring for loved ones who are, to gain a deeper understanding of their lived experiences and treatment journeys.

We are excited to announce updated results from our Phase 2 trial of Descartes-08 in participants with #SLE, with a 100% LLDAS response rate in participants who received Descartes-08, in addition to our expansion into myositis. Read more: https://t.co/m6SMe1kMP1

Today we reported third quarter 2025 financial results and provided a business update. Full press release: https://t.co/DxNspVBJDL #celltherapy #autoimmunity

We joined @MyastheniaOrg Community Health Fairs Walk in D.C., walking with patients, caregivers, and supporters to raise awareness for #myastheniagravis. We’re proud to support this inspiring community and help advance care for those impacted. Learn more: https://t.co/5eO35bZWJ3

October brought some extra fun to Cartesian! To get into the spirit, we celebrated the season with creative costumes and fall treats. Shoutout to our Manufacturing team for winning Best Overall Costume as Gru and his Minions, well deserved! Thanks to everyone who joined in!

Exploring treatment possibilities in #MG? Meet us during the @MyastheniaOrg Scientific Session at #AANEMinSanFran and attend our presentation on the long-term Phase 2b results supporting our ongoing Phase 3 AURORA trial. More details: https://t.co/0AO2IsWTis

We’re heading to #ACR25! Visit booth #973 to learn about our commitment to developing cell therapies for autoimmune diseases. Don’t miss the Lightning Talk on Oct. 26 discussing Descartes-08 clinical updates and expanding CAR-T into #rheumatology! https://t.co/C7C0X1Jp2L

Our commitment to patients drives everything we do. The AURORA Phase 3 trial is evaluating a potential new treatment option for myasthenia gravis (#MG), designed for convenient outpatient dosing and no pretreatment chemo. See if you may qualify: https://t.co/7y49MVy2vb

Our team was honored to volunteer and host dinner at @TheChildrensInn, whose mission is to provide a free “Place Like Home” for children receiving critical medical care. At Cartesian, giving back reinforces our patient first mindset and reminds us why our work matters every day.

Interested in learning more about the promising potential of our Phase 3 AURORA trial as a treatment option for patients with #myastheniagravis? Tune in to the upcoming webinar with @MyastheniaOrg and Cartesian CMO Milos Miljkovic, MD for updates: https://t.co/n4Cy6lSKAg

We wrapped up #WellnessMonth with a themed happy hour that brought our team together in the spirit of relaxation and connection. It was a great way to head into fall with renewed focus and meaning behind our work advancing cell therapies for patients with #autoimmune diseases.

Gratitude was this week’s theme during #WellnessMonth, and our team celebrated with an after-work hike. It was a great way to connect outside the office while taking time to be grateful for our wellness and the people whohelp make our work at Cartesian meaningful.

Looking forward to attending three upcoming investor conferences in September, to discuss expected updates in our pipeline of cell therapies and progress in the Phase 3 AURORA trial in #myastheniagravis. Details here: https://t.co/GA7bDaHcAt #celltherapy

Check out our publication in Annals of Clinical and Translational Neurology, highlighting the durability of response and favorable safety profile of Descartes-08, supporting the continued development in treating #MG. Read here: https://t.co/zHjne2Ed12 @ANA_journals #ACTN

We were proud to host the @FrederickCC and Maryland MEP Biotech Bootcamp at Cartesian headquarters, a hands-on program for those exploring careers in Frederick’s growing #biotech industry. Thanks for visiting and learning what it’s like to work at Cartesian! @frederickworks

#WellnessMonth is underway at Cartesian! We kicked things off with a company-wide walking challenge and this week's theme focused on exercise, complete with lunchtime walks, juice shots, and celebratory bubbles. Here's to a month of healthy habits!

Today we reported second quarter 2025 financial results and provided a business update. Full press release: https://t.co/3WDMtan11B #celltherapy #autoimmunity

Our recently initiated Phase 3 AURORA trial of Descartes-08 in #myastheniagravis is recruiting participants, evaluating an investigational #celltherapy as a potential treatment. To learn more about study locations or get answers about participating, visit: https://t.co/lNtPF5KXig